What lactoferrin actually does

Where it does reasonably well

Iron deficiency in pregnancy is the strongest case, and the scope of that sentence matters. Trials in pregnant women with iron deficiency anemia have compared lactoferrin against ordinary iron tablets and found similar improvement in blood counts, with noticeably fewer digestive complaints. That last part matters more than it sounds: plenty of people abandon iron tablets because of how they feel on them, and a treatment that actually gets taken beats one that does not.

Put a number on “similar”: the pooled analysis covers four trials and 600 pregnant women in total, and the advantage it found traced back to one of them, a trial of 228 women with moderate anemia. The three trials of mild anemia showed no clear difference either way. The dose used was 100 mg twice a day. This is treatment of diagnosed deficiency under supervision, not a reason for anyone to take it generally.

What happened when the same question was asked outside pregnancy

Lactoferrin did worse than the iron tablet. In 2026 a trial in Dhaka, Bangladesh, gave 555 women with iron deficiency anemia who were not pregnant either 200 mg of lactoferrin a day, 400 mg, or an ordinary ferrous sulfate tablet. After 12 weeks, hemoglobin had risen by 1.1 g/dL on the iron tablet. It had slipped by 0.2 g/dL on 200 mg of lactoferrin and had not moved at all on 400 mg. Both lactoferrin doses came out inferior to the iron tablet, and the trial's conclusion was that lactoferrin should not stand in for it.

So the iron answer has two halves, and which one applies depends on who you are. The pregnancy results do not transfer by themselves to a woman who is not pregnant, and the Dhaka trial is the largest test anyone has run on that group. If you are treating anemia you have been diagnosed with, this is a conversation for the doctor or midwife who diagnosed it. For what every trial gave and for how long, see how much lactoferrin per day.

Where the evidence runs out

Most of what is claimed for lactoferrin comes from work in cells or in animals. That research is real and often interesting, but a compound that slows bacterial growth in a dish has not thereby been shown to do anything for a person. The distance between those two statements is the whole problem with how this subject usually gets written about.

Sorting the claims by what each one rests on is the useful exercise, and what lactoferrin is used for does it four ways: what your own body does with the protein, what a laboratory does with it, what food companies have been cleared to add it to, and what a supplement is sold for. The four do not line up.

The two that were tested and failed

Several small trials suggested lactoferrin prevented infections in very premature babies. It was a plausible idea and the early results agreed with each other. A much larger trial then tested it properly in 2,203 infants across 37 UK hospitals, and found no reduction in infection at all. Infections occurred in 29% of the lactoferrin group and 31% of the group given a placebo, a difference well inside the range you would expect from chance.

The second was COVID-19. A 2023 trial in Italy gave 800 mg a day to 218 adults in hospital with moderate to severe disease, and none of its main outcomes differed from placebo: death, admission to intensive care and discharge within 14 days all came out the same.

Both are worth knowing. They answer those two uses, and together they show why a run of small promising trials is not where a story ends.